Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

The ‘KojoX’ method of cloning facilities around the globe keeps the CDMO agile in an industry fractured by geopolitical ...

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Wuxi Biologics highlighted their highly integrated and scaled platform, allowing for end-to-end research, development and manufacturing of complex biologics.

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.